Claeson G, Fareed J, Larsson C, Kindel G, Arielly S, Simonsson R, Messmore H L, Balis J U
Adv Exp Med Biol. 1979;120B:691-713.
The carbonyl terminal tripeptide sequence of bradykinin (Pro-Phe-Arg) is molecularly manipulated to obtain agents with potent antagonistic activity towards the smooth muscle contractile activity of bradykinin. Screening of various peptide derivatives revealed that heptyl amides or esters of H-D-Pro-Phe-Arg, and H-D-Phe-Phe-Arg possessed relatively stronger antibradykinin activity on the isolated smooth muscle preparation. The parent tripeptides, H-D-Pro-Phe-Arg-OH, and H-D-Phe-Phe-Arg-OH, and their amino acid components, i.e. D-Proline, D-Phenylalanine, L-Phenylalanine and Arginine, did not possess any antibradykinin activity in concentrations of up to 10(-4) M. When the heptyl derivatives of these peptides were incubated with either heparinized or citrated whole blood or plasma, the antibradykinin activity was not lost. Incubation of these peptide derivatives with either carboxypeptidase A or B did not result in any loss of the pharmacological effect. However, pancreatic protease extract produced a significant loss of the anti-oxytocic action on the isolated rat uterus preparation. H-D-Pro-Phe-Arg-NH-lauryl derivative also blocked the action of bradykinin and this effect sustained for a longer period of time comparative to the blockade with H-D-Pro-Phe-Arg-NH-heptyl derivative. In concentrations of 10(-7) M and 10(-8) M and 1 min incubation, which blocked the contractile action of bradykinin (1 nmole) on the isolated guinea pig ileum, these peptide derivatives did not block the action of acetylcholine, histamine, and serotonin. However, in concentrations of about 10(-6) M and higher with 5 min. incubation histamin is also blocked. On the isolated rat uterus preparation the contractile action of acetylcholine, angiotensin, oxytocin and vasopressin was blocked at concentrations of 10(-6) M. These findings warrant a differential pharmacological evaluation and in vivo testing of these peptide derivatives to investigate their therapeutic potential.
对缓激肽的羰基末端三肽序列(Pro-Phe-Arg)进行分子操作,以获得对缓激肽的平滑肌收缩活性具有强大拮抗活性的药物。对各种肽衍生物的筛选显示,H-D-Pro-Phe-Arg的庚基酰胺或酯以及H-D-Phe-Phe-Arg对离体平滑肌制剂具有相对较强的抗缓激肽活性。母体三肽H-D-Pro-Phe-Arg-OH和H-D-Phe-Phe-Arg-OH及其氨基酸成分,即D-脯氨酸、D-苯丙氨酸、L-苯丙氨酸和精氨酸,在浓度高达10^(-4) M时不具有任何抗缓激肽活性。当这些肽的庚基衍生物与肝素化或枸橼酸化的全血或血浆一起孵育时,抗缓激肽活性不会丧失。将这些肽衍生物与羧肽酶A或B一起孵育不会导致药理作用的任何丧失。然而,胰腺蛋白酶提取物会使对离体大鼠子宫制剂的抗催产素作用显著丧失。H-D-Pro-Phe-Arg-NH-月桂基衍生物也能阻断缓激肽的作用,与用H-D-Pro-Phe-Arg-NH-庚基衍生物阻断相比,这种作用持续的时间更长。在10^(-7) M和10^(-8) M的浓度下孵育1分钟,可阻断缓激肽(1纳摩尔)对离体豚鼠回肠的收缩作用,这些肽衍生物不会阻断乙酰胆碱、组胺和5-羟色胺的作用。然而,在约10^(-6) M及更高浓度下孵育5分钟时,组胺的作用也会被阻断。在离体大鼠子宫制剂上,乙酰胆碱、血管紧张素、催产素和加压素的收缩作用在10^(-6) M的浓度下被阻断。这些发现保证了对这些肽衍生物进行差异药理学评估和体内试验,以研究它们的治疗潜力。